Verici Dx raises £8.75m through share placing as 2.69bn new shares join AIM

VRCI

Verici Dx Plc (LON:VRCI), a developer of advanced clinical diagnostics for organ transplant, has confirmed that following the passing of the Resolutions at the Shareholders’ General Meeting on Tuesday 27 October 2026, 2,691,999,983 new Ordinary Shares have been admitted to trading on AIM. The Company has raised total gross proceeds of £8.75m (net proceeds of £8.13m) through the Placing and WRAP Retail Offer.

As previously announced, Julian Baines and Sara Barrington, both directors of the Company, participated in the Placing. Following Admission of the Conditional Placing Shares their shareholdings are as set out below:

 Previous HoldingShare Placing ParticipationShareholding following Admission
 Shares%SharesShares%
Julian Baines8,548,4820.37%10,000,00018,548,4820.28%
Sara Barrington8,285,7150.36%5,000,00013,285,7150.20%

Capitalised terms used but not otherwise defined in this announcement have the meanings set out in the Circular published on 10 August 2026.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1Details of the person discharging managerial responsibilities / person closely associated
a)NameJulian Baines
2Reason for the notification
a)Position/statusNon-Executive Chairman
b)Initial notification / AmendmentInitial notification
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameVerici Dx plc
b)LEI213800FI5WE4FVQ3G645
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentIdentification codeOrdinary shares of 0.1 pence each ISIN: GB00BM8HZD43
b)Nature of the transactionPlacing participation of new ordinary shares
c)Price(s) and volume(s)Price:  0.2 penceVolume: 10,000,000 shares 
d)Aggregated informationN/A
e)Date of the transaction28 October 2026
f)Place of the transactionOutside of trading venue – off market 
1Details of the person discharging managerial responsibilities / person closely associated
a)NameSara Barrington
2Reason for the notification
a)Position/statusChief Executive Officer
b)Initial notification / AmendmentInitial notification
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameVerici Dx plc
b)LEI213800FI5WE4FVQ3G645
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentIdentification codeOrdinary shares of 0.1 pence each ISIN: GB00BM8HZD43
b)Nature of the transactionPlacing participation of new ordinary shares
c)Price(s) and volume(s)Price:  0.2 penceVolume: 5,000,000 shares 
d)Aggregated informationN/A
e)Date of the transaction28 October 2026
f)Place of the transactionOutside of trading venue – off market 

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Verici DX reports stronger test adoption and progress towards break-even

Verici DX reported higher test revenue, faster customer adoption and increased orders, while maintaining its target of reaching cash...

Verici Dx targets cash flow breakeven by end of 2027 as US sales expand

Verici Dx is expanding its US sales operation following an £8.75 million fundraising, targeting cash flow breakeven by the...

Kidney Research UK funds new kidney-on-a-chip model to investigate transplant rejection

Kidney Research UK has awarded £110,000 to develop a kidney-on-a-chip model that could help researchers understand transplant rejection, identify...

Verici Dx targets cash-flow breakeven by end of 2027 as Tutivia sales grow

Verici Dx reports 52% year-on-year growth in third-quarter Tutivia orders and targets cash-flow breakeven by the end of 2027....

Verici Dx raises £8.75m through share placing as 2.69bn new shares join AIM

Verici Dx has completed its £8.75m fundraising, with 2.69 billion new ordinary shares admitted to trading on AIM. CEO...

Verici Dx expands kidney transplant research through US clinical trial agreement

Verici Dx has secured an order to provide PTRA and other blood-based biomarker testing for an Asahi Kasei Therapeutics...

Search